Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03137888
Other study ID # IRB00094188
Secondary ID NCI-2017-00424RA
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 20, 2017
Est. completion date January 4, 2025

Study information

Verified date February 2024
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial studies the side effects of spectroscopic magnetic resonance imaging (MRI)-guided radiation therapy and how well it works in treating patients with newly-diagnosed glioblastoma or gliosarcoma. Spectroscopic MRI can show doctors where the extent of tumor is in the brain beyond current clinical MRI scans by mapping areas of high tumor metabolism. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Spectroscopic MRI-guided radiation therapy may work better in treating patients with glioblastoma or gliosarcoma.


Description:

PRIMARY OBJECTIVES: I. To determine the feasibility of using spectroscopic MRI (sMRI) to guide dose-escalated radiation therapy (RT) for newly-diagnosed glioblastoma (GBM)s. II. To determine the safety of using sMRI to guide dose-escalated RT for newly-diagnosed GBMs. SECONDARY OBJECTIVE: I. To determine whether the progression free survival at 1 year with sMRI-guided, dose-escalated RT is improved for newly-diagnosed GBMs. TERTIARY OBJECTIVES: I. To determine whether sMRI-guided, dose-escalated RT increases the overall survival of patients with newly diagnosed GBMs. II. To determine whether sMRI data obtained after initiation of therapy (at 2 weeks after RT/TMZ start and prior to cycle 1 and 5 of adjuvant temozolomide [TMZ]) will provide early evidence of GBM progression not seen on standard MRIs. III. To determine whether performance on neurocognitive and quality-of-life (QOL) assessments in newly-diagnosed GBM patients treated with sMRI-guided, dose-escalated RT differ from historical controls. OUTLINE: Patients undergo sMRI-guided radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide orally (PO) daily during radiation therapy for up to 42 days. After completion of study treatment, patients are followed up every 3 months for up to 2 years and then periodically.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 34
Est. completion date January 4, 2025
Est. primary completion date January 4, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have a newly-diagnosed glioblastoma or gliosarcoma that has been confirmed pathologically by a board-certified neuropathologist - Patients must be able to have MRI scans - Patients must have the following lab values = 14 days prior to registration: - White blood cell (WBC) = 3,000/µL - Absolute neutrophil count (ANC) = 1,500/µL - Platelet count of = 75,000/µL - Hemoglobin = 9.0 gm/dL (transfusion is allowed to reach minimum level) - Serum glutamic-oxaloacetic transaminase (SGOT) = 2.0 x upper limit of normal (ULN) - Bilirubin = 2 x ULN - Creatinine = 1.5 mg/dL - Patients must have a life expectancy of = 12 weeks - Patients must have a Karnofsky performance status (KPS) = 60 - Patients who are women of childbearing potential must have a negative pregnancy test documented = 14 days prior to registration; this is not specific to dose escalation and is mandatory for standard care for patients being treated with radiation therapy; the cost of this test will be covered by standard of care - Patients must be able to understand and provide written informed consent - Members of all races and ethnic groups are eligible for this trial; subjects will be approximately representative of the demographics of the referral base for the participating institutions - Patient must be able to swallow capsules - Patients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol Exclusion Criteria: - Patients with pacemakers, aneurysm clips, neurostimulators, cochlear implants, metal in ocular structures, history of being a steel worker, or other incompatible implants which makes MRI safety an issue are excluded - Patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy are excluded - Patients with a history of any other invasive cancer (except non-melanoma skin cancer and excluding carcinoma in-situ), unless in complete remission and off of all therapy for that disease for = 3 years, are ineligible - Patients with an active infection or serious intercurrent medical illness are ineligible - Patients receiving any other investigational agents are excluded - Patients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excluded - Patients with a history of prior cranial radiation are ineligible - Patients may not be enrolled on any other therapeutic trial for which they are receiving an anti-tumor therapy - Patients with GBMs located in the following anatomical regions known to have magnetic susceptibility or poor signal will be excluded: mesial temporal lobe, orbitofrontal cortex, prefrontal cortex, medial frontal gyrus, brainstem, and cerebellum - The maximum radiation target volume for gross tumor volume 3 (GTV3) is 65 cc (per NRG Oncology guide); patient may be excluded after the first sMRI scan if the GTV3 volume is greater than 65 cc (we anticipate that contrast-enhancing tumor volume [residual tumor volume following tumor resection] would be less than 20 cc)

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Dose-Escalated Radiation Therapy
Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
Procedure:
Spectroscopic Magnetic Resonance Imaging
Patients will undergo sMRI scans within a 14 day window prior to starting treatment
Drug:
Temozolomide
Given PO

Locations

Country Name City State
United States Emory University/Winship Cancer Institute Atlanta Georgia
United States Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland
United States University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida

Sponsors (5)

Lead Sponsor Collaborator
Emory University Johns Hopkins University, National Cancer Institute (NCI), National Institutes of Health (NIH), University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Early evidence of GBM progression assessed by sMRI Changes in sMRI parameters over time will be assessed to determine whether they will be able to predict development of recurrence. At 2 weeks after start of therapy
Other Neurocognitive performance: Hopkins Verbal Learning Test Neurocognitive performance will be assessed by the Hopkins Verbal Learning Test - Revised. Up to 2 years after completion of therapy
Other Neurocognitive performance: Controlled Oral Word Association Test Neurocognitive performance will be assessed by the Controlled Oral Word Association Test (COWAT) from the Multilingual Aphasia Examination. Up to 2 years after completion of therapy
Other Overall survival (OS) The OS actuarial curve and 1-year OS rate will be assessed and compared to historical controls. From the time of surgical resection to the time of death, assessed up to 1 year
Other Quality of life (QOL): European Organization for Research and Treatment of Cancer QOL will be assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30/Brain Cancer Module-20. Up to 2 years after completion of therapy
Other Quality of life (QOL): MD Anderson QOL will be assessed by the MD Anderson Symptom Inventory Brain Tumor Module. Up to 2 years after completion of therapy
Primary Feasibility as assessed by successful co-registration of sMRI-based treatment volumes with clinical images into the radiation treatment execution platform Feasibility of this approach will be determined by whether treatment volumes based on sMRI can be co-registered with clinical images and transferred into the radiation treatment execution platform in a seamless manner, so that sMRI information can be efficiently applied to the patient treatment. Up to 2 years after completion of therapy
Primary Incidence of adverse event assessed by Common Terminology Criteria for Adverse Events version 4.0 The safety of sMRI to guide dose-escalated RT will be confirmed by assessing toxicity potentially attributable to the RT. Up to 2 years after completion of therapy
Secondary Progression free survival (PFS) PFS actuarial curves will be assessed and compared to historical controls, and will particularly interested in comparing the 1-year PFS rate which, based on the control arm (receiving standard dose RT with TMZ) of recent GBM trials, is approximately 30% in historical cohorts. From the time of surgical resection to the time of either radiographic progression or death, whichever occurs first, assessed at 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2